Background: Diabetic ketoacidosis (DKA) is a complex metabolic state of hyperglycaemia, ketosis, and acidosis. Diabetes in sub-Saharan Africa is, in many patients a serious disease with a poor prognosis. Most deaths, however, are due to preventable causes. Objective: To improve knowledge on the management of DKA in sub-Saharan Africa. Data sources: Literature review from different published sources. Data synthesis: Health systems in sub-Saharan Africa are currently organised for the treatment of episodes of illness and not long-term conditions like diabetes. Therefore the high rates of DKA is essentially due to lack of training of health professionals, lack of facilities in most hospitals, lack of public awareness as well as lack of health education to individual patients/families. In addition erratic insulin supply coupling with infections, low parental education, poor insulin storage and lack of facilities for self monitoring of blood glucose. Conclusion: A complex unfavourable social and economic environment is the basis of the high prevalence of DKA in sub-Saharan Africa. Several episodes of DKA can be prevented by effective public awareness programmes and education to healthcare providers.
INTRODUCTION
Diabetic ketoacidosis (DKA) has been recognised as the main complication and potentially fatal emergency in children and adolescents with type 1 diabetes mellitus (T1DM) (1) . Definition of DKA includes hyperglycaemia (blood glucose > 11 mmol/ L [~200 mg/dL]), venous pH <7.3 or bicarbonate <15 mmol/L, in association with ketonemia, ketonuria and glycosuria; occasionally some patients present with normal glycaemic ketoacidosis (2) . A decrease in serum insulin and a glucoregulatory hormones imbalance, causing hyperglycaemia, lipolysis and acidosis, are responsible for developing DKA (1) . DKA occurs all over the world with reported frequency rates higher in developing countries than in the industrialised world. Frequencies of DKA range from 15 to 70% in Europe, Australia and North America (3) (4) (5) . The prevalence rate of diabetes continues to grow in all Western nations (6) , however the prevalence of DKA has remained low, principally following prevention programmes (7) . In developing countries, specifically sub-Saharan Africa very little primary data exist on T1DM and most information depends on anecdote. The few data available estimate the incidence to be 1.5/100,000 in Tanzania (8) , an increase in incidence from 9.5/100,000 in 1991 to 10.3/100,000 in 1995 in Sudan (9) , with the prevalence of DKA ranging between 42 to 76% (10, 11) .
Most healthcare workers are not able to recognise symptoms and signs of DKA in sub-Saharan Africa, which contributes to high rates of DKA at presentation (12) . In fact the report by International Insulin Foundation in three African countries, found that many doctors were scared of insulin and diabetes, and the only training on diabetes they have ever had was during their university education (13) . In contrast it was found that the same health workers were able to recognise all other common diseases in their setting with the resources they have, reflecting the little importance given to diabetes.
DKA at diagnosis is more common in younger children (<5 years of age) and in children whose families do not have readily access to medical care for social or economic reasons (14) , lower income and lack of health insurance (15) . Prevalence of DKA at the time of diagnosis in sub-Saharan Africa was found to be between 70 to 80% (13, 14) . Due to lack of health care workers training and facilities for diagnosis, many children might be misdiagnosed as malaria or meningitis in a busy emergency department of many hospitals in sub-Saharan Africa (16) .
DKA after diagnosis in western countries is in the range of 16 to 36% (6) , in contrast to the rates in Africa which are as high as 76% (11) . These high rates are attributable to erratic insulin supply coupling with infections (11, 14, 17) , low parental education, poor insulin storage as well as lack of facilities for blood glucose monitoring.
The mortality due to DKA in Europe is well below 5% (18, 19) yet in sub-Saharan Africa there has been no reported reduction in mortality rates, stressing further the importance of diabetes awareness, reliable insulin supply and availability of glucose monitoring facilities, both in hospitals and to individual patients.
Strategies are essential for prediction, prevention and successful treatment of DKA in infants, children, and adolescents. Therefore, strategies for management of DKA and its complications in children and adolescents with T1DM are essential. Since there is very little known on T1DM in sub-Saharan Africa this paper aims to review the main aspects of the management and prevention of DKA in children and adolescents in sub-Saharan Africa.
PATHOPHYSIOLOGY OF DKA
Several metabolic alterations are responsible for developing DKA. The primary cause is insulin deficiency, which may be precipitated by infection or other forms of stress. The subsequent increase of glucoregulatory hormones leads to an increased hepatic glyconeogenesis and glycogenolysis leading to an high release of glucose, as well as proteins and fat from muscle and adipose tissues. These metabolic events lead to increased lipolysis and ketone production with the end result of hyperglycaemia, ketonemia, increased plasma osmolarity and kidney glycaemic load. As hyperglycaemia exceeds the renal threshold, it leads to osmotic diuresis, electrolyte loss, and eventually dehydration. The subsequent reduced kidney function is responsible for retention of glucose and increased plasma anion gap.
DKA is generally categorised by the severity of the acidosis, varying from mild DKA (venous pH: <7.30 and/or bicarbonate concentration <15 mmol/ L), moderate DKA (pH: <7.2 and/or bicarbonate: <10mmol/L) to severe DKA (pH: <7.1, and/or bicarbonate: <5 mmol/L) (2, 20) .
MANAGEMENT STRATEGIES
Management of DKA needs to be prompt and helpful to correct metabolic abnormalities. One should identify and treat the precipitating factors and comorbid conditions, set appropriate longterm plan to prevent recurrence and intend to maintain adequate diabetes control. The therapeutic goals consist of replacement of insulin to lower hyperglycaemia and reverse ketogenesis, fluid and electrolyte replacement to correct dehydration and metabolic acidosis and management of precipitating or co-morbid conditions. It is necessary to perform a complete and meticolous physical evaluation to establish gravity of patient's status and its underlying pathogenesis (major components are insulinopenia, infection or physiological stress) ( Tables 1 and 2 (Table 3) . Likewise prevention hinges on avoiding insulin deficiency by regular use of insulin for control of glucose and compensation for stress. Because of the metabolic derangements of DKA, some laboratory tests can be misleading and need to be carefully interpreted.
Since in sub-Saharan Africa one of the most common causes of DKA is infections like pneumonia, malaria, UTI and tuberculosis, screening for infections should be done (1).
TREATMENT
Assessment of the clinical status of the child, laboratory investigations and electrographic monitoring need to be regularly performed: hourly or more frequently if required (Tables 1 and 2 ). However fluid input and output should be assessed.
Fluid and electrolyte therapy:
The first measure towards restoration of fluid and electrolyte deficit is to start venous infusion on the basis of estimated dehydration level (Table 3) . I n c i rc u m s t a n c e s w h e re i n t r a v e n o u s administration is not possible and in a patient with uncomplicated DKA, hourly or after two hours intramuscular administration of short or rapid acting insulin analogs (Insulin lispro or insulin aspart) have been used effectively (26) . This regimen can be used in ambulatory patients where hospitalisation is costly.
Potassium: Reduced potassium is a common feature of ketoacidosis, related to prolonged duration of evolution of DKA, deficit of 3 to 6 mmol/kg (27) . It is unusual to find normal or high potassium at the time of presentation due to the passage of intracellular potassium into the intravascular space masking the actual reduction of the electrolyte. After starting insulin therapy and improvement of acidosis, there is a progressive return of potassium into the cells causing hypokalaemia. If serum potassium is not available before the completion of resuscitation, ECG monitoring is recommended before potassium is added to infusion fluid. Flattening of the wave, widening of the QT interval, and the appearance of U waves indicate hypokalaemia, while tall, peaked, symmetrical T waves and shortening of the QT interval are signs of hyperkalaemia. (i) In hypokalaemic patients, potassium administration as slow infusion should start immediately, before initiation of insulin therapy.
(ii) In normokalaemic patients, potassium replacement is recommended after the first or second hour of treatment. (iii) In hyperkalaemic patients, potassium replacement is delayed until urine output is documented. (iv) The dose of potassium (KCL) is 4-10 mmol/hr in the initial infusion and continues throughout the parenteral infusion (the maximum recommended rate of intravenous potassium replacement is usually 0.5 mmol/kg/hour). Overzealous potassium replacement should be avoided where monitoring is not close.
Sodium:
If serum osmolality fails to rise, and particularly if it falls, careful re-evaluation of fluid replacement is required. Consideration to increase the concentration of sodium chloride is important at this point, however increased vigilance for signs of cerebral oedema is extremely important. The physiological saline will correct the sodium deficit, however: (i) if the serum sodium is <140 mEq/l: 0.9% NaCI should be used. (ii) if the serum sodium is >140 mEq/l: 0.45% NaCI should be used.
Phosphate: Adverse complications of hypophosphatemia are uncommon and occur primarily in patients with severe hypophosphatemia [a serum phosphate concentration of less than 1.0 mg per dL (0.32 mmol per L)] (28). There is no clinical benefit for phosphate replacement in the treatment of DKA, and excessive phosphate replacement may contribute to hypocalcaemia and soft tissue calcification (29) .
Acidosis and sodium bicarbonate replacement:
Usually severe acidosis is reversed by fluid and insulin replacement. Insulin stops further ketones production and allows ketoacids to be metabolised, which generates bicarbonate. By treating hypovolaemia, tissue perfusion is improved hence improvement of renal function with consequent increase in excretion of organic acids. Regarding use of sodium bicarbonate, there are exceptional cases where there is a clear indication to perform bicarbonate infusion. Nevertheless, there may be selected patients who may benefit from bicarbonate therapy. These include patients with severe acidemia (arterial pH <6.9) (30), and those with life-threatening hyperkalaemia. Cautious administration of 1-2 mmol/kg over 60 min may suffice.
To monitor carefully DKA progress and its management, it can be helpful to use the following diary (Figure 1 ).
Figure 1 DKA monitoring chart

COMPLICATIONS
Cerebral oedema: Cerebral oedema is one of the most dreadful complications of DKA in children that require a prompt recognition to reduce related mortality or irreversible neurological damages. Mortality estimates vary widely, but some authors suggest that the disorder is lethal in about 20 to 50% of patients, particularly children (31) . Fortunately, it is a rare occurrence, complicating about 0.5 to 0.9% of cases of DKA (32) .
The pathogenesis of this complication may be complex. A number of mechanisms have been proposed including the role of cerebral ischaemia/ hypoxia and the generation of various inflammatory mediators (33, 34) , increased cerebral blood flow (35) , disruption of cell membrane ion transport (36) and aquaporin channels (37) . The generation of intracellular organic osmolytes (myoinsoitol, taurine) and subsequent cellular osmotic imbalance have also been implicated (38) . Furthermore, high glycaemia and serum sodium levels cause contraction of cell volume due to a fluid shift from the intracellular to the extracellular compartment. By starting therapy, decline in serum osmolality reverses this mechanism with rapid expansion of cerebral intracellular volume causing successive cell swelling and raised intracranial pressure (21) .
Typically, symptomatic cerebral oedema occurs 4-12 hours after the initiation of therapy but cases have also occurred before initiation of therapy (39) and as late as 24-28 hours after the initiation of treatment (40) ( Table 4) . Other complications of DKA are summarised below ( Table 4 Signs and symptoms of cerebral oedema (21, 31) Risk factors for cerebral oedema Signs and symptoms of cerebral oedema • Age <5 years due to immaturity of auto-
Management of cerebral oedema:
• Sudden onset of headache regulatory systems
• Vomiting, blurring of vision • Children with newly diagnosed T1DM
• Bradycardia postural hypotension • Prolonged duration of metabolic derangements • Circulatory compromise • Severe acidosis and low pCO2
• Respiratory failure • Failure of sodium ions to rise as predicted
• Decreased level of consciousness • Papilloedema seizures and coma 
CONCLUSION
There may be an increase in the prevalence of TlDM in children in sub-Saharan Africa, increased awareness of presentation and knowledge of the pathophysiology and management of DKA is imperative. Several episodes of DKA can be prevented by effective public awareness programmes and education to healthcare providers. Therefore, there is an underlined need to inform both physicians and public in order to take up the challenge of reducing the incidence of DKA. Efforts at making insulin available and home monitoring of blood glucose accessible are imperative if the prevalence of DKA is to be reduced and optimise metabolic control of childhood diabetes. Collaboration of governmental and non-governmental agencies in ensuring availability of insulin and other consumables in diabetes care will also go a long way to improve the outcome of children with T1DM.
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